GC Biopharma (KRX:006280) Takes On Some Risk With Its Use Of Debt
Jan 15
Have your own idea? Try our Stock Screener
South Korean (KOSPI) Biotech Industry Analysis
UpdatedJan 18, 2026
DataAggregated Company Financials
Companies124
- 7D-4.2%
- 3M25.8%
- 1Y52.0%
- YTD1.6%
Over the last 7 days, the Biotech industry has dropped 4.2%, driven by Celltrion declining 3.7%. Over the past 12 months, the industry was up 52%. Looking forward, earnings are forecast to grow by 45% annually.
Industry Valuation and Performance
Has the South Korean Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 18 Jan 2026 | ₩171.3t | ₩13.1t | ₩205.3b | 22.4x | 834.3x | 13.1x |
| Tue, 16 Dec 2025 | ₩164.4t | ₩13.1t | ₩274.1b | 26.1x | 599.8x | 12.6x |
| Thu, 13 Nov 2025 | ₩134.8t | ₩12.4t | -₩10,874,806,100.00 | 22.8x | -12399.4x | 10.8x |
| Sat, 11 Oct 2025 | ₩120.9t | ₩12.4t | -₩30,278,124,823.00 | 27.5x | -3992.3x | 9.7x |
| Mon, 08 Sep 2025 | ₩119.2t | ₩12.4t | -₩90,407,979,718.00 | 28.9x | -1318.9x | 9.6x |
| Wed, 06 Aug 2025 | ₩113.4t | ₩11.8t | -₩227,694,607,523.00 | 22.8x | -498.1x | 9.6x |
| Fri, 04 Jul 2025 | ₩109.4t | ₩11.8t | -₩203,233,047,773.00 | 25.4x | -538.1x | 9.3x |
| Sun, 01 Jun 2025 | ₩99.5t | ₩11.8t | -₩158,437,976,105.00 | 28.7x | -628x | 8.4x |
| Tue, 29 Apr 2025 | ₩95.6t | ₩11.4t | -₩456,504,996,975.00 | 27.9x | -209.4x | 8.4x |
| Thu, 27 Mar 2025 | ₩100.8t | ₩11.5t | -₩623,970,804,266.00 | 26.6x | -161.5x | 8.7x |
| Sat, 22 Feb 2025 | ₩98.9t | ₩10.6t | -₩927,517,473,361.00 | 23.9x | -106.6x | 9.3x |
| Mon, 20 Jan 2025 | ₩91.4t | ₩10.5t | -₩1,004,347,149,181.00 | 24.1x | -91x | 8.7x |
| Wed, 18 Dec 2024 | ₩93.5t | ₩8.5t | -₩841,054,767,166.00 | 28.4x | -111.2x | 11x |
| Fri, 15 Nov 2024 | ₩92.7t | ₩10.3t | -₩698,176,939,697.00 | 24x | -132.7x | 9x |
| Sun, 13 Oct 2024 | ₩98.5t | ₩10.3t | -₩653,791,712,887.00 | 26.2x | -150.7x | 9.5x |
| Tue, 10 Sep 2024 | ₩89.9t | ₩10.3t | -₩664,461,088,267.00 | 24x | -135.2x | 8.7x |
| Thu, 08 Aug 2024 | ₩91.0t | ₩9.9t | -₩651,620,427,048.00 | 23.2x | -139.6x | 9.2x |
| Sat, 06 Jul 2024 | ₩85.9t | ₩9.9t | -₩651,620,427,048.00 | 22x | -131.9x | 8.7x |
| Mon, 03 Jun 2024 | ₩78.2t | ₩9.9t | -₩651,185,661,208.00 | 20.3x | -120.1x | 7.9x |
| Wed, 01 May 2024 | ₩82.1t | ₩9.6t | -₩574,854,220,678.00 | 22.3x | -142.7x | 8.5x |
| Fri, 29 Mar 2024 | ₩83.8t | ₩9.5t | -₩596,335,654,327.00 | 23.3x | -140.5x | 8.8x |
| Sun, 25 Feb 2024 | ₩77.3t | ₩9.7t | -₩534,696,541,747.00 | 62.7x | -144.5x | 7.9x |
| Tue, 23 Jan 2024 | ₩74.3t | ₩9.7t | -₩537,261,689,777.00 | 63.4x | -138.3x | 7.6x |
| Thu, 21 Dec 2023 | ₩62.5t | ₩10.1t | -₩311,749,314,637.00 | 28.5x | -200.4x | 6.2x |
| Sat, 18 Nov 2023 | ₩57.8t | ₩10.2t | -₩268,639,297,229.00 | 28.3x | -215.2x | 5.7x |
| Mon, 16 Oct 2023 | ₩54.7t | ₩10.2t | -₩239,053,318,689.00 | 28x | -229x | 5.4x |
| Wed, 13 Sep 2023 | ₩59.8t | ₩10.2t | -₩338,340,868,849.00 | 33.2x | -176.7x | 5.9x |
| Fri, 11 Aug 2023 | ₩60.7t | ₩10.3t | -₩166,675,753,149.00 | 32.1x | -364.5x | 5.9x |
| Sun, 09 Jul 2023 | ₩55.4t | ₩10.3t | -₩151,534,704,579.00 | 26.5x | -365.3x | 5.4x |
| Tue, 06 Jun 2023 | ₩63.5t | ₩10.3t | -₩151,338,675,579.00 | 31.2x | -419.4x | 6.2x |
| Thu, 04 May 2023 | ₩60.4t | ₩11.0t | ₩317.9b | 24.1x | 190x | 5.5x |
| Sat, 01 Apr 2023 | ₩57.4t | ₩11.0t | ₩319.9b | 23.6x | 179.5x | 5.2x |
| Mon, 27 Feb 2023 | ₩57.2t | ₩11.3t | ₩968.6b | 24.7x | 59.1x | 5.1x |
| Wed, 25 Jan 2023 | ₩58.7t | ₩11.3t | ₩970.8b | 24.1x | 60.4x | 5.2x |
Price to Earnings Ratio
60.4x
Current Industry PE
- Investors are optimistic on the South Korean Biotechs industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 834x which is higher than its 3-year average PE of -479x.
- The 3-year average PS ratio of 8.0x is lower than the industry's current PS ratio of 13.1x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have declined 40% per year over the last three years.
- Meanwhile revenues for these companies have grown 5.1% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the South Korean Healthcare industry?
| KR Market | 5.06% | |
| Healthcare | -1.74% | |
| Biotech | -4.20% | |
| Biotech | -4.20% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| A196170 ALTEOGEN | ₩518.00k | 1.4% +₩374.4b | 68.5% | PE220x | |
| A174900 AbClon | ₩57.60k | 6.9% +₩106.3b | 335.7% | PS299x | |
| A950160 Kolon TissueGene | ₩74.70k | 1.5% +₩91.5b | 144.9% | PS1224.5x | |
| A0120G0 Samyang Biopharm | ₩62.40k | 18.9% +₩73.6b | n/a | n/a | |
| A302440 SK bioscienceLtd | ₩48.80k | 1.6% +₩58.8b | -1.4% | PS6.1x |
